Novo Nordisk 2024 Outlook: Now Expects Sales Growth Of 22%-28% (Prior 19%-27%) And Operating Profit Growth Of 20%-28% (Prior 22%-30%)
Portfolio Pulse from Benzinga Newsdesk
Novo Nordisk has updated its 2024 outlook, now expecting sales growth of 22%-28% and operating profit growth of 20%-28%. The revised guidance reflects higher expectations for both North America and International Operations, driven by volume growth in GLP-1-based treatments for Obesity and Diabetes care, despite continued pricing pressure.
August 07, 2024 | 6:51 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Novo Nordisk has raised its 2024 sales growth outlook to 22%-28% and operating profit growth to 20%-28%, driven by strong performance in GLP-1-based treatments for Obesity and Diabetes care.
The updated guidance indicates stronger-than-expected performance, particularly in key treatment areas, which is likely to positively impact investor sentiment and the stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100